Evidence map›Paper›PMID 41423820›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Chemical Synthesis of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii Capsular Polysaccharide Fragments as Leads for Cross-Protection.

Amar Kumar Mishra, Emelie E Reuber, Diksha Rai, Leif E Sander, Julia Duerr, Simon Y Graeber, Marcus A Mall, Bettina C Fries, Peter H Seeberger, Suvarn S Kulkarni

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amar Kumar MishraDepartment of Chemistry, Indian Institution of Technology Bombay, Powai, Mumbai, India.
Emelie E ReuberInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Diksha RaiDepartment of Chemistry, Indian Institution of Technology Bombay, Powai, Mumbai, India.
Leif E SanderDepartment of Infectious Diseases and Critical Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität, and Humboldt-Universität zu Berlin, Berlin, Germany.
Julia DuerrGerman Center for Lung Research (DZL), Associated Partner Site Berlin, Berlin, Germany.
Simon Y GraeberGerman Center for Lung Research (DZL), Associated Partner Site Berlin, Berlin, Germany.
Marcus A MallGerman Center for Lung Research (DZL), Associated Partner Site Berlin, Berlin, Germany.
Bettina C FriesDepartment of Microbiology and Immunology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, 11794, USA.
Peter H SeebergerInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0003-3394-8466
Suvarn S KulkarniDepartment of Chemistry, Indian Institution of Technology Bombay, Powai, Mumbai, India.ORCID 0000-0003-2884-876X

Funding

German Federal Ministry of Research 01GL2401AGerman Federal Ministry of Research 82DZL009C1German Research Foundation 431232613German Research Foundation 533770413Science and Education Research Board SPR/2021/000328
6 · The paper itself

Abstract

Pseudomonas aeruginosa and Staphylococcus aureus are listed by the World Health Organization as high-priority multidrug-resistant (MDR) pathogens, whereas Acinetobacter baumannii is classified as the critical-priority group. These bacteria cause life-threatening infections such as severe bloodstream, nosocomial, urinary tract, and soft-tissue infections. Their cell surfaces display complex and structurally distinct glycans absent in host cells, making them targets for glycoconjugate vaccine and diagnostic research. In this study, we report the chemical synthesis of mono- and oligosaccharide fragments derived from three ESKAPE pathogens, P. aeruginosa O11, S. aureus (CP5, CP8, and strain M), and A. baumannii (S34 and O5), as well as Plesiomonas shigelloides O1. Glycan microarray screening revealed three epitopes exhibiting strong cross-reactive immunogenicity against P. aeruginosa, S. aureus, and A. baumannii, demonstrating that a trisaccharide represents the minimal epitope required to elicit cross-protective immune responses. The key features of P. aeruginosa O11 trisaccharide synthesis involve efficient assembly of a 1,2-cis-linked l-FucNAc-linker motif, followed by regioselective glycosylation at O3 and subsequently at O2 of the d-Glc-l-FucNAc-linker disaccharide. The same strategy was applied for assembling its tetrasaccharide fragment. Additionally, β-mannosylation and 1,2-cis-d-FucNAc linkage formations were optimized for the S. aureus CP8 fragment, establishing a versatile route toward bacterial glycans relevant for vaccine and diagnostic development.

Indexed as

Acinetobacter baumanniiPolysaccharidesPolysaccharides, BacterialPseudomonas aeruginosaStaphylococcus aureusPolysaccharidesPolysaccharides, BacterialESKAPE pathogensGlycan immunologyMicroarray studiesRare deoxy amino sugarsTotal synthesis

Identifiers

PMID41423820
PMCPMC12865246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.